RuncheyResearch

Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive

Back to Forecasting

NVO Forecast Markets

Novo Nordisk A/S

7
Active Markets
1
Resolved
41%
Avg Probability
Price Below Value
Feb 12, 2026

Our prediction ensemble suggests potential upside from current levels.

7 markets analyzedConfidence: MEDIUM
Read Full Thesis

All Markets

8 markets

Will Novo Nordisk report Q1 2026 adjusted sales decline greater than 10% YoY at constant exchange rates?

Active
32%
Likely No
79% agreement
Jun 15, 2026
IG: 0.80

Will more than 60% of oral Wegovy prescriptions through Q2 2026 go to patients without a prior injectable GLP-1 prescription in the preceding 12 months?

Active
52%
Likely Yes
60% agreement
Sep 30, 2026
IG: 0.80

Will the FDA approve Eli Lilly's orforglipron (oral GLP-1) by September 30, 2026?

Active
66%
Likely Yes
81% agreement
Oct 15, 2026
IG: 0.64

Will oral Wegovy (semaglutide pill for obesity) reach 100,000 weekly US prescriptions by September 30, 2026?

Active
44%
Likely No
76% agreement
Oct 31, 2026
IG: 0.64

Will Novo Nordisk's actual US net price reductions under the MFN agreement exceed the company's guided assumptions by more than 2 percentage points by December 31, 2026?

Active
28%
Likely No
83% agreement
Feb 28, 2027
IG: 0.64

Will the FDA take enforcement action against at least 3 major compounding pharmacies selling semaglutide products by December 31, 2026?

Active
34%
Likely No
84% agreement
Jan 31, 2027
IG: 0.48

Will a US federal court grant class certification in any Ozempic/Wegovy product liability lawsuit by December 31, 2026?

Active
7%
Likely No
92% agreement
Jan 31, 2027
IG: 0.48

Will CagriSema demonstrate >=20% body weight loss in the REDEFINE 4 trial results reported by June 30, 2026?

Resolved
62%
Likely Yes
Actual: NO
Brier: 0.384
Feb 23, 2026
IG: 0.80

Resolution Timeline

Jun 15, 2026
Will Novo Nordisk report Q1 2026 adjusted sales decline greater than 10% YoY at constant exchange rates?
Prediction: 32%
Jul 31, 2026RESOLVED
Will CagriSema demonstrate >=20% body weight loss in the REDEFINE 4 trial results reported by June 30, 2026?
NOBrier: 0.38
Sep 30, 2026
Will more than 60% of oral Wegovy prescriptions through Q2 2026 go to patients without a prior injectable GLP-1 prescription in the preceding 12 months?
Prediction: 52%
Oct 15, 2026
Will the FDA approve Eli Lilly's orforglipron (oral GLP-1) by September 30, 2026?
Prediction: 66%
Oct 31, 2026
Will oral Wegovy (semaglutide pill for obesity) reach 100,000 weekly US prescriptions by September 30, 2026?
Prediction: 44%
Jan 31, 2027
Will the FDA take enforcement action against at least 3 major compounding pharmacies selling semaglutide products by December 31, 2026?
Prediction: 34%
Jan 31, 2027
Will a US federal court grant class certification in any Ozempic/Wegovy product liability lawsuit by December 31, 2026?
Prediction: 7%
Feb 28, 2027
Will Novo Nordisk's actual US net price reductions under the MFN agreement exceed the company's guided assumptions by more than 2 percentage points by December 31, 2026?
Prediction: 28%